Search results for Nrg1 Fusions

IMA histology should trigger RNA sequencing in NSCLC – here’s why

RNA sequencing enables detection of NRG1 fusions in invasive mucinous adenocarcinoma, ensuring accurate molecular profiling and identification of actionable targets often missed by...

<![CDATA[FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma]]>

A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy

Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific an...

Medgenome unveils india’s first study demonstrating the clinical impact of RNA-based NGS in sarcoma diagnosis

RNA sequencing improves sarcoma diagnosis by detecting gene fusions and refining classifications, enabling more accurate treatment decisions and better patient...

Oncogenic Signaling Shaped by a Golgi Trafficking Protein Pair

A new study shows that the Golgi proteins GOLPH3 and MYO18A control delivery of RTKs to the cell surface, defining signaling strength and revealing a potential vulnerability in RTK...

FUSILLI -long-read fusion detection

RNA sequencing with FUSILLI improves detection of leukemia fusion oncogenes, supporting more accurate molecular diagnosis and subtyping in pediatric B-cell acute lymphoblastic leuk...

Thioredoxin Reductase 3 Fuels EGFR Inhibitor Resistance

In a groundbreaking study poised to reshape our understanding of therapeutic resistance in aggressive cancers, researchers have unveiled a novel molecular mechanism underlying trea...

ALK Mutation Identified as a Predictive Biomarker for Pan-Cancer Immunotherapy

A groundbreaking study published in Genes & Diseases has unveiled the crucial role of anaplastic lymphoma kinase (ALK) mutations across multiple cancer types in predicting robu...

Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zen...

LEXINGTON, Mass., April 14, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announces the submission of a supplemental Bio...